These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28430172)

  • 41. EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.
    Szumera-CieĆkiewicz A; Poleszczuk J; Paszkiewicz-Kozik E; Rymkiewicz G; SokÓŁ K; Borysiuk A; Kotarska M; Owczarek D; Kawecka M; Pytlak B; Walewski J; Prochorec-Sobieszek M
    Anticancer Res; 2020 Dec; 40(12):6685-6697. PubMed ID: 33288562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
    Yan KS; Lin CY; Liao TW; Peng CM; Lee SC; Liu YJ; Chan WP; Chou RH
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.
    Dubuc AM; Remke M; Korshunov A; Northcott PA; Zhan SH; Mendez-Lago M; Kool M; Jones DT; Unterberger A; Morrissy AS; Shih D; Peacock J; Ramaswamy V; Rolider A; Wang X; Witt H; Hielscher T; Hawkins C; Vibhakar R; Croul S; Rutka JT; Weiss WA; Jones SJ; Eberhart CG; Marra MA; Pfister SM; Taylor MD
    Acta Neuropathol; 2013 Mar; 125(3):373-84. PubMed ID: 23184418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma.
    Larrea E; Fernandez-Mercado M; Guerra-Assunção JA; Wang J; Goicoechea I; Gaafar A; Ceberio I; Lobo C; Okosun J; Enright AJ; Fitzgibbon J; Lawrie CH
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.
    Li H; Kaminski MS; Li Y; Yildiz M; Ouillette P; Jones S; Fox H; Jacobi K; Saiya-Cork K; Bixby D; Lebovic D; Roulston D; Shedden K; Sabel M; Marentette L; Cimmino V; Chang AE; Malek SN
    Blood; 2014 Mar; 123(10):1487-98. PubMed ID: 24435047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.
    Korfi K; Ali S; Heward JA; Fitzgibbon J
    Epigenetics; 2017 May; 12(5):370-377. PubMed ID: 28106467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
    Bradley WD; Arora S; Busby J; Balasubramanian S; Gehling VS; Nasveschuk CG; Vaswani RG; Yuan CC; Hatton C; Zhao F; Williamson KE; Iyer P; Méndez J; Campbell R; Cantone N; Garapaty-Rao S; Audia JE; Cook AS; Dakin LA; Albrecht BK; Harmange JC; Daniels DL; Cummings RT; Bryant BM; Normant E; Trojer P
    Chem Biol; 2014 Nov; 21(11):1463-75. PubMed ID: 25457180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional relationship of SNP (Ala490Thr) of an epigenetic gene
    Gautam N; Verma H; Choudhary S; Kaur S; Silakari O
    J Genet; 2021; 100():. PubMed ID: 34825659
    [No Abstract]   [Full Text] [Related]  

  • 51. EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.
    Lian R; Ma H; Wu Z; Zhang G; Jiao L; Miao W; Jin Q; Li R; Chen P; Shi H; Yu W
    Mol Cell Biochem; 2018 Feb; 439(1-2):35-43. PubMed ID: 28795320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity.
    Yin J; Leavenworth JW; Li Y; Luo Q; Xie H; Liu X; Huang S; Yan H; Fu Z; Zhang LY; Zhang L; Hao J; Wu X; Deng X; Roberts CW; Orkin SH; Cantor H; Wang X
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15988-93. PubMed ID: 26668377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
    Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S
    Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
    Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
    Sashida G; Iwama A
    Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic and epigenetic inactivation of
    Oricchio E; Katanayeva N; Donaldson MC; Sungalee S; Pasion JP; Béguelin W; Battistello E; Sanghvi VR; Jiang M; Jiang Y; Teater M; Parmigiani A; Budanov AV; Chan FC; Shah SP; Kridel R; Melnick AM; Ciriello G; Wendel HG
    Sci Transl Med; 2017 Jun; 9(396):. PubMed ID: 28659443
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EZH2 Y641 mutations in follicular lymphoma.
    Bödör C; O'Riain C; Wrench D; Matthews J; Iyengar S; Tayyib H; Calaminici M; Clear A; Iqbal S; Quentmeier H; Drexler HG; Montoto S; Lister AT; Gribben JG; Matolcsy A; Fitzgibbon J
    Leukemia; 2011 Apr; 25(4):726-9. PubMed ID: 21233829
    [No Abstract]   [Full Text] [Related]  

  • 58. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing.
    Nuytten M; Beke L; Van Eynde A; Ceulemans H; Beullens M; Van Hummelen P; Fuks F; Bollen M
    Oncogene; 2008 Feb; 27(10):1449-60. PubMed ID: 17724462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.
    Caretti G; Di Padova M; Micales B; Lyons GE; Sartorelli V
    Genes Dev; 2004 Nov; 18(21):2627-38. PubMed ID: 15520282
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
    Christofides A; Karantanos T; Bardhan K; Boussiotis VA
    Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.